Mean Platelet Volume in Crohn’s Disease Patients Predicts Sustained Response to a 52-Week Infliximab Therapy: A Pilot Study
Open Access
- 6 October 2015
- journal article
- research article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 61 (2) , 542-549
Abstract
Background The loss of response to infliximab in Crohn’s disease (CD) patients is currently a major clinical problem. Recently, mean platelet volume (MPV) has been proposed as a new biomarker of CD activity. Here, we hypothesized that MPV may be used as cheap and efficient biomarker of subclinical inflammation during 52-week therapy in CD patients responding to infliximab induction treatment. Aims The aim of study was to establish whether MPV at baseline and pre-infusion at week 14 are good predictors of sustained response after week 14 in CD patients undergoing 52-week infliximab therapy. Methods A retrospective study of 30 adult CD patients who underwent a 52-week course of treatment with infliximab and achieved response at week 14 to induction treatment was performed. The association between MPV, baseline disease parameters and maintained clinical response or remission during infliximab therapy was assessed. Results Higher MPV at week 14 was observed in CD patients with sustained response to infliximab after week 14 than in patients with loss of response (p = 0.0019). In patients with loss of response to maintenance infliximab treatment, lower ΔMPV between baseline and week 14 was calculated (p = 0.0003). MPV > 10.3 fl at week 14 predicts sustained response with 67 % sensitivity and 80 % specificity. ΔMPV between baseline and week 14 >0.4 fl predicts sustained response with 87 % sensitivity and 93 % specificity. Conclusion MPV at week 14 and ΔMPV between baseline and week 14 are good predictors of sustained response to infliximab maintenance treatment in CD patients.Keywords
This publication has 22 references indexed in Scilit:
- Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trialGut, 2013
- Compartmentalized Expression of Th1 and Th17 Cytokines in Pediatric Inflammatory Bowel DiseasesInflammatory Bowel Diseases, 2012
- Potential Role of Mycoplasma hominis in Interleukin (IL)–17–Producing CD4+ T-Cell Generation Via Induction of IL-23 Secretion by Human Dendritic CellsThe Journal of Infectious Diseases, 2011
- Review article: loss of response to anti-TNF treatments in Crohn’s diseaseAlimentary Pharmacology & Therapeutics, 2011
- Mean platelet volume in patients with rheumatoid arthritis: the effect of anti-TNF-alpha therapyRheumatology International, 2010
- An overlooked indicator of disease activity in ulcerative colitis: Mean platelet volumePlatelets, 2009
- Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritisJoint Bone Spine, 2008
- Role of Interleukin-1β in Activating the CD11chighCD45RB−Dendritic Cell Subset and PrimingLeishmania amazonensis- Specific CD4+T Cells In Vitro and In VivoInfection and Immunity, 2007
- Laboratory Values for Children With Newly Diagnosed Inflammatory Bowel DiseasePediatrics, 2007
- Platelet sizeBlood Coagulation & Fibrinolysis, 1996